Risk factors for treatment related clinical fluctuations in Guillain-Barré syndrome

Journal of Neurology Neurosurgery and Psychiatry

Volumn 64, Issue 2, 1998, Pages 242-244

  Visser, L H ^a,b   Van Der Meche F G A ^a   Meulstee, J ^a   Van Doorn, P A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b CPRLab   (Netherlands)

Author keywords

Guillain Barr syndrome; Risk factors; Treatment; Treatment related fluctuations

Indexed keywords

IMMUNOGLOBULIN; METHYLPREDNISOLONE;

ARTICLE; DISEASE COURSE; ELECTRODIAGNOSIS; GUILLAIN BARRE SYNDROME; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; PLASMAPHERESIS; PRIORITY JOURNAL; RELAPSE; RISK ASSESSMENT; RISK FACTOR;

EID: 0031895141     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.64.2.242     Document Type: Article

References (14)

1. The Guillain-Barré study group. Plasmapheresis and acute Guillain-Barré syndrome. Neurology 1985;35:1096-104.
2. French Cooperative Group on plasma exchange in Guillain-Barré Syndrome. Efficiency of plasma exchange in Guillain-Barré syndrome: role of replacement fluids. Ann Neurol 1987;22:753-61.
3. van der Meché FGA, Schmitz PIM, Dutch Guillain-Barré Study Group. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. N Engl J Med 1992;326:1123-9.
4. McKhann GM, Griffin JW, Cornblath DR, et al. Plasmapheresis and Guillain-Barré syndrome: analysis of prognostic factors and the effect of plasmapheresis. Ann Neurol 1988;23:347-53.
5. Winer JB, Hughes RAC, Osmond C. A prospective study of acute idiopathic neuropathy. I. Clinical features and their prognostic value. J Neurol Neurosurg Psychiatry 1988;51: 605-12.
6. The French Cooperative group on plasma exchange in Guillain-Barré syndrome. Appropriate number of plasma exchanges in Guillain-Barré syndrome. Ann Neurol 1997; 41:298-306.
7. Osterman PO, Fagius J, Safwenberg J, et al. Early relapse of acute inflammatory polyradiculoneuropathy after successful treatment with plasma exchange. Acta Neurol Scand 1988;77:273-7.
8. Ropper AE, Albert JW, Addison R. Limited relapse in Guillain-Barré syndrome after plasma exchange. Arch Neurol 1988;45:314-5.
9. Kleyweg RP, van der Meché FGA. Treatment related fluctuations in Guillain-Barré syndrome after high-dose immunoglobulins or plasma-exchange. J Neurol Neurosurg Psychiatry 1991;54:957-60.
10. The Dutch Guillain-Barré Study Group. Treatment of Guillain-Barré syndrome with high-dose immune globulins combined with methylprednisolone: a pilot study. Ann Neurol 1994;35:749-52.
11. Kleyweg RP, van der Meché FGA, Schmitz PIM. Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barré syndrome. Muscle Nerve 1991;14:1103-9.
12. Visser LH, van der Meché FGA, van Doorn PA, et al. Guillain-Barré syndrome without sensory loss (acute motor neuropathy). A subgroup with specific clinical, electrodiagnostic and laboratory features. Dutch Guillain-Barré Study Group. Brain 1995;118:841-7.
13. Visser LH, van der Meché FGA, Meulstee J, et al. Cytomegalovirus infection and Guillain-Barré syndrome; the clinical, electrophysiologic and prognostic features. Neurology 1996;47:668-73.
14. Meulstee J, van der Meché FGA, Dutch Guillain-Barré Study Group. Electrodiagnostic criteria for polyneuropathy and demyelination: application in 135 patients with Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 1995;59:482-6.